Equities research analysts expect that Natera Inc (NASDAQ:NTRA) will post earnings per share of ($0.50) for the current quarter, Zacks reports. Four analysts have issued estimates for Natera’s earnings. The highest EPS estimate is ($0.38) and the lowest is ($0.60). Natera posted earnings of ($0.73) per share in the same quarter last year, which suggests a positive year over year growth rate of 31.5%. The firm is expected to announce its next quarterly earnings results on Tuesday, March 12th.
According to Zacks, analysts expect that Natera will report full year earnings of ($2.18) per share for the current financial year, with EPS estimates ranging from ($2.31) to ($1.98). For the next financial year, analysts forecast that the firm will post earnings of ($1.18) per share, with EPS estimates ranging from ($1.30) to ($0.96). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Natera.
Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, November 8th. The medical research company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.03). Natera had a negative net margin of 58.00% and a negative return on equity of 2,569.52%. The business had revenue of $65.30 million during the quarter, compared to the consensus estimate of $66.42 million. During the same quarter in the prior year, the firm posted ($0.51) EPS. The company’s revenue for the quarter was up 16.8% compared to the same quarter last year.
Several research analysts recently commented on the stock. BidaskClub lowered shares of Natera from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 30th. Zacks Investment Research lowered shares of Natera from a “hold” rating to a “sell” rating in a research note on Wednesday, October 10th. TheStreet lowered shares of Natera from a “c-” rating to a “d+” rating in a research note on Tuesday, October 9th. Cowen reiterated a “buy” rating and set a $30.00 price objective on shares of Natera in a research note on Friday, November 9th. Finally, Canaccord Genuity boosted their price objective on shares of Natera from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, August 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $28.25.
Shares of NASDAQ:NTRA traded down $0.72 during trading hours on Monday, hitting $16.97. The company’s stock had a trading volume of 458,109 shares, compared to its average volume of 700,611. Natera has a 52 week low of $8.60 and a 52 week high of $29.62. The company has a debt-to-equity ratio of 1.30, a quick ratio of 2.32 and a current ratio of 2.44. The firm has a market cap of $1.09 billion, a P/E ratio of -7.07 and a beta of 2.03.
In other Natera news, insider Jonathan Sheena sold 166,667 shares of the business’s stock in a transaction that occurred on Friday, September 14th. The shares were sold at an average price of $24.27, for a total transaction of $4,045,008.09. Following the sale, the insider now owns 481,975 shares of the company’s stock, valued at approximately $11,697,533.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Matthew Rabinowitz sold 403,462 shares of the business’s stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $24.90, for a total transaction of $10,046,203.80. Following the sale, the chief executive officer now directly owns 1,701,686 shares in the company, valued at approximately $42,371,981.40. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,014,988 shares of company stock valued at $48,674,710. 13.18% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in NTRA. Dupont Capital Management Corp purchased a new stake in Natera during the 2nd quarter worth approximately $526,000. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Natera during the 2nd quarter worth approximately $815,000. Perkins Capital Management Inc. purchased a new stake in Natera during the 2nd quarter worth approximately $482,000. Jennison Associates LLC grew its position in Natera by 1.4% during the 2nd quarter. Jennison Associates LLC now owns 2,617,623 shares of the medical research company’s stock worth $49,264,000 after purchasing an additional 36,876 shares during the last quarter. Finally, State of Wisconsin Investment Board grew its position in Natera by 30.4% during the 2nd quarter. State of Wisconsin Investment Board now owns 30,000 shares of the medical research company’s stock worth $565,000 after purchasing an additional 7,000 shares during the last quarter. 87.90% of the stock is currently owned by institutional investors.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Recommended Story: Futures Contract
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.